


CHEMICAL COMPOUNDSABSTRACT

The present invention concerns compounds of general formula (I):



in which:

R^1 represents hydrogen, R^4 , $-C(=Y)-NHR^4$, $-SO_2NHR^4$, $-C(=Z^1)-R^4$, $-SO_2-R^4$ or $-C(=Z^1)-OR^4$;

R^2 represents hydrogen, cyano, halogen or $-C\equiv C-R^5$;

R^3 represents hydrogen, acyl, alkoxycarbonyl, alkyl, aroyl, aryl, aryloxy carbonyl, carboxy, cycloalkenyl, cycloalkyl, heteroaroyl, heteroaryl, heterocycloalkyl or $-C(=O)-NY^1Y^2$;

R^4 represents optionally substituted alkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl or heteroaryl

R^5 represents hydrogen or alkyl;

R^6 represents alkyl, acyl, alkoxycarbonyl, alkylsulfonyl, aryl, arylsulfonyl, aroyl, cycloalkyl, cycloalkenyl, heteroaryl, heteroarylsulfonyl, heteroaroyl and heterocycloalkyl;

R^7 represents optionally substituted alkyl, cycloalkyl or cycloalkylalkyl,

R^8 represents hydrogen, alkyl, alkenyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl;

R^9 represents alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl;

R^{10} represents hydrogen or lower alkyl;

R^{11} represents alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl; or alkyl optionally substituted by $-NY^1Y^2$;

R^{12} represents aryl or heteroaryl; or alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl or heterocycloalkylalkyl each optionally substituted

Y represents O, S or NCN;

Y^1 and Y^2 (Y^3 and Y^4) are independently in particular hydrogen, alkyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl or heterocycloalkyl; or the group $-NY^1Y^2$ may form 5-7 membered ring or the group $-NY^3Y^4$ ($-NY^5Y^6$) may form a cyclic amine;

Z (Z^1) represents O or S; Z^2 represents O or $S(O)_p$; n is zero or an integer 1 or 2;

m is 1 or 2; p is 1 or 2;

and their corresponding N-oxides, their prodrugs; their pharmaceutically acceptable salts and solvates (e.g. hydrates), also together with one or more pharmaceutically acceptable carriers or excipients, such novel indolizines derivatives with inhibitory effects towards kinase proteins and especially for use for preventing or treating diseases that may be modulated by the inhibition of such kinase proteins and particularly solid tumours.